Humanwell Healthcare Group Co Ltd banner

Humanwell Healthcare Group Co Ltd
SSE:600079

Watchlist Manager
Humanwell Healthcare Group Co Ltd Logo
Humanwell Healthcare Group Co Ltd
SSE:600079
Watchlist
Price: 18.6 CNY 0.05% Market Closed
Market Cap: ¥30.4B

EV/GP

3
Current
14%
Cheaper
vs 3-y average of 3.5

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
3
=
Enterprise Value
¥35.5B
/
Gross Profit
¥11.5B

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
3
=
Enterprise Value
¥35.5B
/
Gross Profit
¥11.5B

Valuation Scenarios

Humanwell Healthcare Group Co Ltd is trading below its 3-year average

If EV/GP returns to its 3-Year Average (3.5), the stock would be worth ¥21.63 (16% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+348%
Average Upside
133%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 3 ¥18.6
0%
3-Year Average 3.5 ¥21.63
+16%
5-Year Average 3.6 ¥21.91
+18%
Industry Average 7.6 ¥46.32
+149%
Country Average 13.6 ¥83.24
+348%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
CN
Humanwell Healthcare Group Co Ltd
SSE:600079
30.4B CNY 3 16.4
US
Eli Lilly and Co
NYSE:LLY
825.8B USD 15.5 39
US
Johnson & Johnson
NYSE:JNJ
548.5B USD 8.8 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 6.3 20.1
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 6.3 27.5
CH
Novartis AG
SIX:NOVN
220.1B CHF 6.8 19.5
US
Merck & Co Inc
NYSE:MRK
272.3B USD 5.8 15
IE
Endo International PLC
LSE:0Y5F
244.4B USD 160.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 4.9 11.1
US
Pfizer Inc
NYSE:PFE
150.6B USD 4.2 19.2
US
Bristol-Myers Squibb Co
NYSE:BMY
117.3B USD 4.2 16.4

Market Distribution

Lower than 90% of companies in China
Percentile
10th
Based on 6 967 companies
10th percentile
3
Low
0 — 8
Typical Range
8 — 23.3
High
23.3 —
Distribution Statistics
China
Min 0
30th Percentile 8
Median 13.6
70th Percentile 23.3
Max 17 898 541.1

Humanwell Healthcare Group Co Ltd
Glance View

Market Cap
30.4B CNY
Industry
Pharmaceuticals

In the rapidly evolving landscape of the Chinese pharmaceutical industry, Humanwell Healthcare Group Co Ltd. stands as a multifaceted player with its roots deeply embedded in both innovation and tradition. Founded in Wuhan, Humanwell has cultivated a robust portfolio that extends beyond the manufacture and distribution of pharmaceuticals, marking its presence in fields like anesthetics, reproductive health products, and specialty chemicals. Anchoring its operations is a commitment to research and development, investing significantly in new technologies and drug formulations. Humanwell leverages its extensive manufacturing capabilities and adheres to rigorous quality controls, enabling it to efficiently produce and market a diverse array of products across domestic and international markets. The company’s financial structure is bolstered by a savvy integration of its capabilities and strategic partnerships, enhancing both its market reach and product offerings. With subsidiaries spread across different continents, Humanwell taps into the lucrative supply chains of the healthcare sector, accentuating its revenue streams. Through strategic acquisitions and partnerships, the company has invested in expanding its global footprint, enhancing its competitive prowess. This tactical expansion, coupled with a keen focus on understanding and fulfilling consumer needs, allows Humanwell Healthcare not only to sustain a strong financial performance but also to play a pivotal role in shaping the future of the healthcare market in China and beyond.

Intrinsic Value
30.38 CNY
Undervaluation 39%
Intrinsic Value
Price ¥18.6
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett